Beyond secretases: Kinase inhibitors for the treatment of Alzheimer's disease

Federico Medda, Breland Smith, Vijay Gokhale, Arthur Y. Shaw, Travis Dunckley, Christopher Hulme

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the most prevalent form of dementia in old age. Recent data indicate that 24.3 million people worldwide suffer from AD. Hyperphosphorylation of tau, a protein normally involved in microtubule stabilization, has been identified as an important pathological contributor to AD development. In AD brains, hyperphosphorylation of tau leads to its aggregation, misfolding, and formation of neurofibrillary tangles, one common hallmark of AD. Specific protein kinases, such as GSK-3β, CDK5, and DYRK1A, are involved in tau hyperphosphorylation and have been identified as potential targets for the development of novel therapeutic agents for the treatment of AD cognitive deficits. We herein review the current state of the art in the development of small molecule inhibitors of GSK-3β, CDK5, DYRK1A, and other protein kinases involved in tau phosphorylation. Only recently developed compounds with cellular and/or in vivo activity will be discussed.

Original languageEnglish (US)
Pages (from-to)57-71
Number of pages15
JournalAnnual Reports in Medicinal Chemistry
Volume48
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Amyloid Precursor Protein Secretases
Alzheimer Disease
Phosphotransferases
Glycogen Synthase Kinase 3
Protein Kinases
tau Proteins
Neurofibrillary Tangles
Phosphorylation
Microtubules
Dementia
Brain
Agglomeration
Stabilization
Molecules
Proteins

Keywords

  • Alzheimer's disease
  • CDK5
  • DYRK1A
  • ERK2
  • GSK-3β
  • JNK3
  • Neurodegenerative diseases
  • Neurofibrillary tangles
  • Protein kinases
  • Tau protein

ASJC Scopus subject areas

  • Biochemistry
  • Organic Chemistry

Cite this

Beyond secretases : Kinase inhibitors for the treatment of Alzheimer's disease. / Medda, Federico; Smith, Breland; Gokhale, Vijay; Shaw, Arthur Y.; Dunckley, Travis; Hulme, Christopher.

In: Annual Reports in Medicinal Chemistry, Vol. 48, 01.01.2013, p. 57-71.

Research output: Contribution to journalArticle

Medda, Federico ; Smith, Breland ; Gokhale, Vijay ; Shaw, Arthur Y. ; Dunckley, Travis ; Hulme, Christopher. / Beyond secretases : Kinase inhibitors for the treatment of Alzheimer's disease. In: Annual Reports in Medicinal Chemistry. 2013 ; Vol. 48. pp. 57-71.
@article{a43b1a672e134b0aa3d1ed3ea7db7e2e,
title = "Beyond secretases: Kinase inhibitors for the treatment of Alzheimer's disease",
abstract = "Alzheimer's disease (AD) is the most prevalent form of dementia in old age. Recent data indicate that 24.3 million people worldwide suffer from AD. Hyperphosphorylation of tau, a protein normally involved in microtubule stabilization, has been identified as an important pathological contributor to AD development. In AD brains, hyperphosphorylation of tau leads to its aggregation, misfolding, and formation of neurofibrillary tangles, one common hallmark of AD. Specific protein kinases, such as GSK-3β, CDK5, and DYRK1A, are involved in tau hyperphosphorylation and have been identified as potential targets for the development of novel therapeutic agents for the treatment of AD cognitive deficits. We herein review the current state of the art in the development of small molecule inhibitors of GSK-3β, CDK5, DYRK1A, and other protein kinases involved in tau phosphorylation. Only recently developed compounds with cellular and/or in vivo activity will be discussed.",
keywords = "Alzheimer's disease, CDK5, DYRK1A, ERK2, GSK-3β, JNK3, Neurodegenerative diseases, Neurofibrillary tangles, Protein kinases, Tau protein",
author = "Federico Medda and Breland Smith and Vijay Gokhale and Shaw, {Arthur Y.} and Travis Dunckley and Christopher Hulme",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/B978-0-12-417150-3.00005-3",
language = "English (US)",
volume = "48",
pages = "57--71",
journal = "Annual Reports in Medicinal Chemistry",
issn = "0065-7743",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Beyond secretases

T2 - Kinase inhibitors for the treatment of Alzheimer's disease

AU - Medda, Federico

AU - Smith, Breland

AU - Gokhale, Vijay

AU - Shaw, Arthur Y.

AU - Dunckley, Travis

AU - Hulme, Christopher

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Alzheimer's disease (AD) is the most prevalent form of dementia in old age. Recent data indicate that 24.3 million people worldwide suffer from AD. Hyperphosphorylation of tau, a protein normally involved in microtubule stabilization, has been identified as an important pathological contributor to AD development. In AD brains, hyperphosphorylation of tau leads to its aggregation, misfolding, and formation of neurofibrillary tangles, one common hallmark of AD. Specific protein kinases, such as GSK-3β, CDK5, and DYRK1A, are involved in tau hyperphosphorylation and have been identified as potential targets for the development of novel therapeutic agents for the treatment of AD cognitive deficits. We herein review the current state of the art in the development of small molecule inhibitors of GSK-3β, CDK5, DYRK1A, and other protein kinases involved in tau phosphorylation. Only recently developed compounds with cellular and/or in vivo activity will be discussed.

AB - Alzheimer's disease (AD) is the most prevalent form of dementia in old age. Recent data indicate that 24.3 million people worldwide suffer from AD. Hyperphosphorylation of tau, a protein normally involved in microtubule stabilization, has been identified as an important pathological contributor to AD development. In AD brains, hyperphosphorylation of tau leads to its aggregation, misfolding, and formation of neurofibrillary tangles, one common hallmark of AD. Specific protein kinases, such as GSK-3β, CDK5, and DYRK1A, are involved in tau hyperphosphorylation and have been identified as potential targets for the development of novel therapeutic agents for the treatment of AD cognitive deficits. We herein review the current state of the art in the development of small molecule inhibitors of GSK-3β, CDK5, DYRK1A, and other protein kinases involved in tau phosphorylation. Only recently developed compounds with cellular and/or in vivo activity will be discussed.

KW - Alzheimer's disease

KW - CDK5

KW - DYRK1A

KW - ERK2

KW - GSK-3β

KW - JNK3

KW - Neurodegenerative diseases

KW - Neurofibrillary tangles

KW - Protein kinases

KW - Tau protein

UR - http://www.scopus.com/inward/record.url?scp=84884139734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884139734&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-417150-3.00005-3

DO - 10.1016/B978-0-12-417150-3.00005-3

M3 - Article

AN - SCOPUS:84884139734

VL - 48

SP - 57

EP - 71

JO - Annual Reports in Medicinal Chemistry

JF - Annual Reports in Medicinal Chemistry

SN - 0065-7743

ER -